Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye

Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye
zeebizindia@gmail.com (Zee Business)
© Provided by Zee Business
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Swati Khandelwal, Zee Business.
Edited Excerpts: 
Q: The company has posted good numbers but the market expected that your numbers will be even better. What would you like to say about the overall numbers? Also, tell us about the challenges that you faced in this quarter?

Related Keywords

South Africa ,India ,Swati Khandelwal ,Kedar Upadhye ,Eli Lilly ,Facebook ,Cipla ,Global Chief Finance Officer ,Edited Excerpts ,Zee Business Tweet Video Below ,Liposomal Amphotericin ,இந்தியா ,சுவாதி கண்டெழுவாள் ,கெதர் உபபதியே ,எலி லில்லி ,முகநூல் ,சிப்லா ,ஸீ வணிக ட்வீட் காணொளி கீழே ,